Grisnilimab setaritox  (Synonyms: WT1-RTA)

Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID₅₀ of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys^[1].

Grisnilimab setaritox (2.5 μg/mL; 24 h) is cytotoxic to CEM cells (T-lymphoblastic leukemia)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Grisnilimab setaritox (60 μg, 120 μg; i.t. or i.v.; single dose) have the potential to inhibit T-ALL meningoleukemia in a rhesus monkey model of leukemic meningitis^[1].
Grisnilimab setaritox (60 μg; i.v.; once weekly for 6 weeks or daily for 7 days) leads to CSF granulocytosis and anti-immunotoxin antibodies in rhesus monkey model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2361013-29-6

[Grisnilimab setaritox]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66.  [Content Brief]